ANALYSIS: With an Obermatt 360° View of 49 (better than 49% compared with alternatives), overall professional sentiment and financial characteristics for the stock Fulcrum Therapeutics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for Fulcrum Therapeutics. The consolidated Value Rank has an attractive rank of 58, which means that the share price of Fulcrum Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 58% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 52, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 65. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 4. Professional investors are more confident in 96% other stocks. ...read more